Compare MPB & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | DSGN |
|---|---|---|
| Founded | 1868 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 819.6M |
| IPO Year | 1996 | 2021 |
| Metric | MPB | DSGN |
|---|---|---|
| Price | $33.49 | $12.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $37.00 | $15.25 |
| AVG Volume (30 Days) | 116.0K | ★ 881.5K |
| Earning Date | 04-21-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | $91.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.50 | $3.33 |
| 52 Week High | $35.22 | $17.25 |
| Indicator | MPB | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 58.30 |
| Support Level | $30.82 | $11.94 |
| Resistance Level | $34.88 | $13.54 |
| Average True Range (ATR) | 0.83 | 0.63 |
| MACD | 0.07 | 0.24 |
| Stochastic Oscillator | 66.50 | 88.26 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.